Table 1 Clinical characteristics of patients pre and post therapy.

From: Teprotumumab for the treatment of chronic thyroid eye disease

Case

VA OD pre

VA OS pre

VA OD post

VA OS post

CAS OD pre

CAS OS pre

CAS OD post

CAS OS post

Hertel OD pre

Hertel OS pre

Hertel OD post

Hertel OS post

Gorman score Pre

Gorman score post

1

20/30

20/100

20/30

20/100

2

3

1

1

18

19

16

14

4

2

2

20/50

20/30

20/30

20/30

3

4

1

1

23

22

20

19

0

0

3

20/25

20/20

20/25

20/20

3

3

2

2

21

21

20

20

4

4

4

20/20

20/20

20/20

20/20

1

3

0

0

20

25

17

20

1

1

5

20/20

20/20

20/20

20/20

2

2

0

0

19

21

17

18

1

1

6

20/25

20/25

20/25

20/25

3

3

0

0

24

24

20

20

0

0

7

20/20

20/20

20/20

20/20

2

2

0

0

21

24

19

21

3

0

8

20/20

20/20

20/20

20/20

3

3

1

1

20

21

18

19

0

0

9

20/20

20/20

20/20

20/20

3

3

1

1

23

24

18

19

0

0

10

20/20

20/20

20/20

20/20

1

1

1

1

25

27

22

22

0

0

11

20/40

20/50

20.40

20/50

1

2

0

0

20

20

19

19

0

0

12

20/20

20/20

20/20

20/20

1

1

0

0

20

21

18

19

0

0

13

20/20

20/20

20/20

20/20

1

1

0

0

20

21

18

19

0

0

14

20/25

20/40

20/30

20/25

1

1

1

1

28

27

26

25

4

4

15

20/30

20/30

20/30

20/30

3

3

1

1

25

25

23

21

0

0

16

20/30

20/25

20/25

20/25

3

3

0

0

18

19

17

17

2

1

17

20/20

20/30

20/20

20/20

2

2

0

0

29

28

25

26

1

0

18

20/80

20/25

20/80

20/25

2

2

1

1

28

25

20

17

2

1

19

20/25

20/20

20/20

20/20

3

3

0

0

25

25

24

24

0

0

20

20/25

20/20

20/25

20/20

1

1

0

0

22

20

19

17

2

0

21

20/25

20/25

20/25

20/40

1

1

0

0

30

30

22

25

0

0

22

CF

HM

20/400

CF

3

0

0

0

24

30

15

25

0

0

23

HM

HM

CF

HM

3

3

1

1

35

35

33

31

0

0

24

20/20

20/20

20/20

20/20

3

3

0

0

21

22

19

19

2

0

25

20/25

20/60

20/20

20/40

3

3

0

0

17

23

13.5

16

3

3

26

20/60

20/50

20/50

20/40

2

2

0

0

24

24

20

21

2

0

27

20/40

20/70

20/25

20/25

3

3

0

0

24.5

24

20.5

20.5

0

0

28

20/40

20/30

20/25

20/30

3

3

2

2

23

24

20

21

0

0

29

20/40

20/20

20/20

20/40

3

3

2

2

20

20.5

17

18

3

0

30

20/30

20/30

20/30

20/30

3

3

0

0

32

32.5

26

28

2

0

31

20/20

20/25

20/25

20/25

3

1

3

1

18

19

18

15

0

0

  1. VA visual acuity, CAS clinical activity score.